Yara Abdou, MD (IMAGE)
Caption
“The good news is there has been a significant increase in industry investment in cancer clinical trials, leading to advancements in cancer therapies and a reduction in cancer mortality,” said Yara Abdou, MD, UNC Lineberger member and assistant professor of medicine and breast cancer specialist at UNC School of Medicine. “However, the bad news is the lack of growth in federally funded trial enrollment, which often addresses broader and underrepresented research areas that industry sponsors tend to avoid.”
Credit
UNC Lineberger Comprehensive Cancer Center
Usage Restrictions
None
License
Original content